MIR31HG and hepatocellular carcinoma: Nevertheless, the expression levels of MIR31HG was reported down-regulated in triple-negative breast cancer (TNBC) cell lines of basal subtype [27], bladder cancer [26], gastric cancer [25], CRC [32, 33], and HCC [6].